Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study

PRIMARY OBJECTIVES:

I. Evaluate cardiovascular reserve capacity, as measured by peak oxygen consumption (VO2peak), in hematopoietic cell transplantation (HCT) survivors.

II. Define the determinants of VO2peak impairment in HCT survivors.

OUTLINE:

Patients undergo echocardiogram to assess cardiac function and mechanics, cardiopulmonary exercise test, pulmonary function test, musculoskeletal ultrasound, bioelectrical impedance analysis to measure total lean body mass and percent body fat), physical function tests, and collection of blood samples within 45 days from the start of conditioning therapy, and at 6 months, 1 year, and 2 years post-transplant.

Inclusion criteria

• Age at HCT >= 18 years
• Diagnosis of acute leukemia (myeloid, lymphoid), lymphoma (non-Hodgkin, Hodgkin), multiple myeloma or myelodysplastic syndromes
• Planning to undergo first autologous or allogeneic transplant
• Able to fluently read and write in English
• Able to understand and sign the study specific informed consent form (ICF)
• Physically able and willing to complete all study procedures

Exclusion criteria

• Unstable bone lesions per electronic medical record review and/or notification from patient's primary physician
• Unstable angina or history of acute myocardial Infarction (< 5 days of any planned study procedures)
• Recurrent syncope
• Acute myocarditis or pericarditis
• Symptomatic severe aortic stenosis
• Uncontrolled arrhythmia causing symptoms
• Pulmonary embolus < 3 month of study procedures
• Thrombosis of lower extremities
• Moderate or severe persistent asthma (National Asthma Education & Prevention)
• Room air desaturation at rest =< 85%
• Non-cardiopulmonary disorders that may affect exercise performance or be aggravated by exercise (i.e. infection, renal failure, thyrotoxicosis)
• Anemia (hemoglobin [Hgb] < 8 g/dL)